论文部分内容阅读
用功能正常的器官(或组织)来替换患者功能缺损的器官,即移植疗法,是本世纪医学界取得的重大成果,并为医学科学作出了重要贡献.但是,早期的临床移植由于出现严重的移植排斥反应而遭受了痛苦和血的教训.免疫学和移植学的发展,引入了一些预防和治疗免疫排斥反应的方法,特别是免疫抑制药物的运用,使临床移植成功率得到提高.在现行应用的免疫抑制药物中,微生物来源的免疫抑制药物以它作用的针对性强、副反应少而独具应用优势.虽然免疫耐受的临床研究成为探索解决器官移植问题的又一途径,但是免疫耐受研究存在的问题,以及临床实施中仍可能用到免疫抑制药物,使得新型免疫抑制药物的开发保持有强大的生命力.本文将对这方面的研究进展作一综述.
Replacing organ dysfunction organs, known as transplantation therapies, with a functioning organ (or tissue) is a major achievement in the medical community of the century and has made a significant contribution to medical science, but early clinical transplants, due to the presence of severe Transplant rejection and suffered pain and blood of the lessons of the development of immunology and transplantation, the introduction of a number of prevention and treatment of immune rejection methods, in particular, the use of immunosuppressive drugs, the clinical transplant success rate has been improved in the current Among the immunosuppressive drugs used, the immunosuppressive drugs derived from microorganisms are highly targeted and have few side effects, which are uniquely applied advantages.Although the clinical research of immune tolerance has become another way to solve the problem of organ transplantation, Tolerant research, and immunosuppressive drugs may still be used in clinical practice, so that the development of new immunosuppressive drugs will maintain a strong vitality.This article reviews the research progress in this field.